Market News AIOpen the app

PYXS stock news · Pyxis Oncology

Stories about Pyxis Oncology (PYXS) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for PYXS

Follow Pyxis Oncology (PYXS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PYXS
Free on the App Store and Google Play, or on the web.
  1. Nov 19, 2026, 9:14 AM ET · Trial

    Pyxis Oncology shared new Phase 1 results for micvotabart pelidotin, showing a 39% response rate in head and neck cancer patients.

    Good for PYXS

    Pyxis Oncology reported a 39% confirmed response rate and plans a global Phase 3 study for MICVO. These results support progress, but are still from Phase 1.

  2. Sep 30, 2026, 1:17 PM ET · Market

    12 health care companies are seeing big changes in their stock prices today.

    Neutral

    Pyxis Oncology shares fell 25% to $2.18. The article gives no company news explaining the move, so it does not change the business outlook.

  3. Sep 30, 2026, 8:45 AM ET · Market

    12 health care companies are changing prices before the market opens on Wednesday.

    Neutral

    The report says PYXS shares fell 13.8%, but gives no company news or reason for the drop. That alone does not show a change in its business outlook.

  4. Sep 9, 2026, 1:44 PM ET · Market

    An analyst points out important safety issues with Pyxis Oncology's cancer drug.

    Neutral

    Pyxis released Phase 1 efficacy and safety data showing strong responses and also high severe side effects; I read this as neutral for Pyxis.